<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278082</url>
  </required_header>
  <id_info>
    <org_study_id>BUC-63/COC</org_study_id>
    <secondary_id>2007-001315-31</secondary_id>
    <nct_id>NCT01278082</nct_id>
  </id_info>
  <brief_title>SOIBD Collagenous Colitis Maintenance Study</brief_title>
  <acronym>SCCMS</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Budesonide Capsules Versus Placebo for Maintenance of Remission in Patients With Collagenous Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Organization for Studies on Inflammatory Bowel Disease</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate the superiority of budesonide compared to placebo as&#xD;
      maintenance therapy in keeping patients in remission over a one-year period&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients being in remission over 52 weeks.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Remission is defined as a mean of &lt; 3 stools/day, thereof a mean of &lt; 1 watery stools/day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission at wk 4, 13, 26, and 39.</measure>
    <time_frame>39 weeks</time_frame>
    <description>Remission is defined as a mean of &lt; 3 stools/day, thereof a mean of &lt; 1 watery stools/day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Induction and Maintaining Remission of Collagenous Colitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Budenofalk 3mg capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent,&#xD;
&#xD;
          2. Patients aged &gt;= 18 years,&#xD;
&#xD;
          3. Histologically established diagnosis of collagenous colitis (CC) defined as:&#xD;
&#xD;
               1. Thickened sub-epithelial collagen layer &gt;= 10 µm on well-orientated sections,&#xD;
&#xD;
               2. Increased amount of inflammatory cells indicating chronic inflammation in the&#xD;
                  lamina propria,&#xD;
&#xD;
          4. History of non-bloody, watery diarrhoea for more than 2 weeks prior screening in&#xD;
             patients with newly diagnosed collagenous colitis, or history of clinical relapse for&#xD;
             more than 1 week prior screening in patients with previously established collagenous&#xD;
             colitis,&#xD;
&#xD;
          5. A mean of &gt;= 3 stools/day, thereof a mean of &gt;= 1 watery stools/day, during the week&#xD;
             prior baseline,&#xD;
&#xD;
          6. Women of child-bearing potential and being heterosexually active have to apply&#xD;
             appropriate contraceptive methods, e.g., hormonal contraception, intrauterine device&#xD;
             (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide),&#xD;
             or partner has undergone vasectomy. The investigator is responsible for determining&#xD;
             whether the subject has adequate birth control for study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other significant abnormalities at colonoscopy that may have been the cause of&#xD;
             diarrhoea, with the exception of colonic diverticulosis and polyps &lt; 2 cm,&#xD;
&#xD;
          2. Infectious cause of diarrhoea,&#xD;
&#xD;
          3. Untreated active celiac disease,&#xD;
&#xD;
          4. Clinical suspicion of drug-induced collagenous colitis,&#xD;
&#xD;
          5. Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder,&#xD;
&#xD;
          6. Abnormal hepatic function (ALT or ALP &gt; 2.5 x upper limit of normal [ULN]), liver&#xD;
             cirrhosis, or portal hypertension,&#xD;
&#xD;
          7. Local intestinal infection,&#xD;
&#xD;
          8. Radiation therapy towards the abdominal or pelvic region,&#xD;
&#xD;
          9. Diabetes mellitus, infection, glaucoma, tuberculosis, peptic ulcer disease, or&#xD;
             hypertension if careful medical monitoring is not ensured,&#xD;
&#xD;
         10. Known established cataract,&#xD;
&#xD;
         11. Known hereditary problems of galactose or fructose intolerance, glucose-galactose&#xD;
             malabsorption, sucrase-isomaltase insufficiency, Lapp lactase deficiency, or&#xD;
             congenital lactase deficiency,&#xD;
&#xD;
         12. Established osteoporosis with T-score &lt; -2.5,&#xD;
&#xD;
         13. Pregnancy or lactation,&#xD;
&#xD;
         14. History of cancer in the last five years,&#xD;
&#xD;
         15. History of significant bowel resection,&#xD;
&#xD;
         16. Therapy with immunomodulators (azathioprine, 6-mercaptopurine, or methotrexate) in the&#xD;
             last 3 months,&#xD;
&#xD;
         17. Treatment with oral, rectal, or intravenous corticosteroids including budesonide in&#xD;
             the last month,&#xD;
&#xD;
         18. Known intolerance/hypersensitivity to study drug or drugs of similar chemical&#xD;
             structure or pharmacological profile,&#xD;
&#xD;
         19. Patients who are unable to adhere to the study visit schedule and other protocol&#xD;
             requirements according to the judgement of the investigator,&#xD;
&#xD;
         20. Participation in another clinical trial within the last 30 days, simultaneous&#xD;
             participation in another clinical trial, or previous participation in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Müller, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Falk Pharma GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of digestive diseases</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Linköping</name>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Münch A, Bohr J, Miehlke S, Benoni C, Olesen M, Öst Å, Strandberg L, Hellström PM, Hertervig E, Armerding P, Stehlik J, Lindberg G, Björk J, Lapidus A, Löfberg R, Bonderup O, Avnström S, Rössle M, Dilger K, Mueller R, Greinwald R, Tysk C, Ström M; BUC-63 investigators. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut. 2016 Jan;65(1):47-56. doi: 10.1136/gutjnl-2014-308363. Epub 2014 Nov 25.</citation>
    <PMID>25425655</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Randomized</keyword>
  <keyword>double-blind</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>budesonide</keyword>
  <keyword>collagenous colitis</keyword>
  <keyword>acute treatment</keyword>
  <keyword>maintaining remission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Collagenous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

